Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 83 entries
Sorted by: Best Match Show Resources per page
Treatment of wounds colonized by multidrug resistant organisms in immune-compromised patients: a retrospective case series.

Patient safety in surgery

Pignatti M, Gerunda GE, Rompianesi G, De Ruvo N, Di Benedetto F, Codeluppi M, Bonucchi D, Pacchioni L, Loschi P, Malaventura C, De Santis G.
PMID: 24139428
Patient Saf Surg. 2013 Sep 03;7(1):28. doi: 10.1186/1754-9493-7-28.

BACKGROUND: Immune-compromised patients incur a high risk of surgical wound dehiscence and colonization by multidrug resistant organisms. Common treatment has been debridement and spontaneous secondary healing.We report on the results obtained in nine such patients whose wounds were treated...

Cite
Pignatti M, Gerunda GE, Rompianesi G, et al. Treatment of wounds colonized by multidrug resistant organisms in immune-compromised patients: a retrospective case series. Patient Saf Surg. 2013;7(1):28doi: 10.1186/1754-9493-7-28.
Pignatti, M., Gerunda, G. E., Rompianesi, G., De Ruvo, N., Di Benedetto, F., Codeluppi, M., Bonucchi, D., Pacchioni, L., Loschi, P., Malaventura, C., & De Santis, G. (2013). Treatment of wounds colonized by multidrug resistant organisms in immune-compromised patients: a retrospective case series. Patient safety in surgery, 7(1), 28. https://doi.org/10.1186/1754-9493-7-28
Pignatti, Marco, et al. "Treatment of wounds colonized by multidrug resistant organisms in immune-compromised patients: a retrospective case series." Patient safety in surgery vol. 7,1 (2013): 28. doi: https://doi.org/10.1186/1754-9493-7-28
Pignatti M, Gerunda GE, Rompianesi G, De Ruvo N, Di Benedetto F, Codeluppi M, Bonucchi D, Pacchioni L, Loschi P, Malaventura C, De Santis G. Treatment of wounds colonized by multidrug resistant organisms in immune-compromised patients: a retrospective case series. Patient Saf Surg. 2013 Sep 03;7(1):28. doi: 10.1186/1754-9493-7-28. PMID: 24139428; PMCID: PMC3847491.
Copy Download .nbib Format: NLM
Two stage hip revision in periprosthetic infection: results of 41 cases.

The open orthopaedics journal

Pignatti G, Nitta S, Rani N, Dallari D, Sabbioni G, Stagni C, Giunti A.
PMID: 20721319
Open Orthop J. 2010 Jun 11;4:193-200. doi: 10.2174/1874325001004010193.

BACKGROUND: two-stage revision is considered the best treatment approach for the eradication of chronic joint infection. We report the outcome of 41 consecutive patients with infected hip prostheses, treated between 2000 and 2005, with two-stage revision using an antibiotic-loaded...

Cite
Pignatti G, Nitta S, Rani N, et al. Two stage hip revision in periprosthetic infection: results of 41 cases. Open Orthop J. 2010;4:193-200doi: 10.2174/1874325001004010193.
Pignatti, G., Nitta, S., Rani, N., Dallari, D., Sabbioni, G., Stagni, C., & Giunti, A. (2010). Two stage hip revision in periprosthetic infection: results of 41 cases. The open orthopaedics journal, 4193-200. https://doi.org/10.2174/1874325001004010193
Pignatti, Giovanni, et al. "Two stage hip revision in periprosthetic infection: results of 41 cases." The open orthopaedics journal vol. 4 (2010): 193-200. doi: https://doi.org/10.2174/1874325001004010193
Pignatti G, Nitta S, Rani N, Dallari D, Sabbioni G, Stagni C, Giunti A. Two stage hip revision in periprosthetic infection: results of 41 cases. Open Orthop J. 2010 Jun 11;4:193-200. doi: 10.2174/1874325001004010193. PMID: 20721319; PMCID: PMC2923340.
Copy Download .nbib Format: NLM
Joint Instability After Anatomic Reconstruction of Severe, Chronic Slipped Capital Femoral Epiphysis: A Report of 3 Cases, with High Femoral Anteversion in 1 and Adaptive Acetabular Roof Deformation in 3.

JBJS case connector

Ganz R, Aprato A, Mazziotta G, Pignatti G.
PMID: 29252682
JBJS Case Connect. 2016 Apr-Jun;6(2):e50. doi: 10.2106/JBJS.CC.15.00149.

CASES: Joint instability after slipped capital femoral epiphysis (SCFE) reorientation through the physis has been attributed to a combination of capsulotomy and chondrolabral rim damage. We report on 3 hips with severe SCFE with closed physes, in which anatomic...

Cite
Ganz R, Aprato A, Mazziotta G, et al. Joint Instability After Anatomic Reconstruction of Severe, Chronic Slipped Capital Femoral Epiphysis: A Report of 3 Cases, with High Femoral Anteversion in 1 and Adaptive Acetabular Roof Deformation in 3. JBJS Case Connect. 2016;6(2):e50doi: 10.2106/JBJS.CC.15.00149.
Ganz, R., Aprato, A., Mazziotta, G., & Pignatti, G. (2016). Joint Instability After Anatomic Reconstruction of Severe, Chronic Slipped Capital Femoral Epiphysis: A Report of 3 Cases, with High Femoral Anteversion in 1 and Adaptive Acetabular Roof Deformation in 3. JBJS case connector, 6(2), e50. https://doi.org/10.2106/JBJS.CC.15.00149
Ganz, Reinhold, et al. "Joint Instability After Anatomic Reconstruction of Severe, Chronic Slipped Capital Femoral Epiphysis: A Report of 3 Cases, with High Femoral Anteversion in 1 and Adaptive Acetabular Roof Deformation in 3." JBJS case connector vol. 6,2 (2016): e50. doi: https://doi.org/10.2106/JBJS.CC.15.00149
Ganz R, Aprato A, Mazziotta G, Pignatti G. Joint Instability After Anatomic Reconstruction of Severe, Chronic Slipped Capital Femoral Epiphysis: A Report of 3 Cases, with High Femoral Anteversion in 1 and Adaptive Acetabular Roof Deformation in 3. JBJS Case Connect. 2016 Apr-Jun;6(2):e50. doi: 10.2106/JBJS.CC.15.00149. PMID: 29252682.
Copy Download .nbib Format: NLM
European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

ESMO open

Tzogani K, Florez B, Markey G, Caleno M, Olimpieri OM, Melchiorri D, Hovgaard DJ, Sarac SB, Penttilä K, Lapveteläinen T, Salmonson T, Bergh J, Gisselbrecht C, Pignatti F.
PMID: 31555488
ESMO Open. 2019 Sep 08;4(5):e000570. doi: 10.1136/esmoopen-2019-000570. eCollection 2019.

On 21 November 2016, the European Commission issued a marketing authorisation valid throughout the European Union for ixazomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one...

Cite
Tzogani K, Florez B, Markey G, et al. European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. ESMO Open. 2019;4(5):e000570doi: 10.1136/esmoopen-2019-000570.
Tzogani, K., Florez, B., Markey, G., Caleno, M., Olimpieri, O. M., Melchiorri, D., Hovgaard, D. J., Sarac, S. B., Penttilä, K., Lapveteläinen, T., Salmonson, T., Bergh, J., Gisselbrecht, C., & Pignatti, F. (2019). European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. ESMO open, 4(5), e000570. https://doi.org/10.1136/esmoopen-2019-000570
Tzogani, Kyriaki, et al. "European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy." ESMO open vol. 4,5 (2019): e000570. doi: https://doi.org/10.1136/esmoopen-2019-000570
Tzogani K, Florez B, Markey G, Caleno M, Olimpieri OM, Melchiorri D, Hovgaard DJ, Sarac SB, Penttilä K, Lapveteläinen T, Salmonson T, Bergh J, Gisselbrecht C, Pignatti F. European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. ESMO Open. 2019 Sep 08;4(5):e000570. doi: 10.1136/esmoopen-2019-000570. eCollection 2019. PMID: 31555488; PMCID: PMC6735670.
Copy Download .nbib Format: NLM
Antibiotic drug not always the culprit: Allergy to a homoeopathic product.

International journal of clinical practice

Marraccini P, Lari SA, Conforti E, Pignatti P.
PMID: 32168405
Int J Clin Pract. 2020 Jul;74(7):e13500. doi: 10.1111/ijcp.13500.

No abstract available.

Cite
Marraccini P, Lari SA, Conforti E, et al. Antibiotic drug not always the culprit: Allergy to a homoeopathic product. Int J Clin Pract. 2020;74(7):e13500doi: 10.1111/ijcp.13500.
Marraccini, P., Lari, S. A., Conforti, E., & Pignatti, P. (2020). Antibiotic drug not always the culprit: Allergy to a homoeopathic product. International journal of clinical practice, 74(7), e13500. https://doi.org/10.1111/ijcp.13500
Marraccini, Paolo, et al. "Antibiotic drug not always the culprit: Allergy to a homoeopathic product." International journal of clinical practice vol. 74,7 (2020): e13500. doi: https://doi.org/10.1111/ijcp.13500
Marraccini P, Lari SA, Conforti E, Pignatti P. Antibiotic drug not always the culprit: Allergy to a homoeopathic product. Int J Clin Pract. 2020 Jul;74(7):e13500. doi: 10.1111/ijcp.13500. PMID: 32168405.
Copy Download .nbib Format: NLM
The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia.

HemaSphere

Delgado J, Voltz C, Stain M, Balkowiec-Iskra E, Mueller B, Wernsperger J, Malinowska I, Gisselbrecht C, Enzmann H, Pignatti F.
PMID: 34291195
Hemasphere. 2021 Jul 19;5(8):e616. doi: 10.1097/HS9.0000000000000616. eCollection 2021 Aug.

Luspatercept is a recombinant fusion protein that selectively binds to ligands belonging to the transforming growth factor-beta superfamily, resulting in erythroid maturation and differentiation. On June 25, 2020, a marketing authorization valid through the European Union (EU) was issued...

Cite
Delgado J, Voltz C, Stain M, et al. The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia. Hemasphere. 2021;5(8):e616doi: 10.1097/HS9.0000000000000616.
Delgado, J., Voltz, C., Stain, M., Balkowiec-Iskra, E., Mueller, B., Wernsperger, J., Malinowska, I., Gisselbrecht, C., Enzmann, H., & Pignatti, F. (2021). The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia. HemaSphere, 5(8), e616. https://doi.org/10.1097/HS9.0000000000000616
Delgado, Julio, et al. "The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia." HemaSphere vol. 5,8 (2021): e616. doi: https://doi.org/10.1097/HS9.0000000000000616
Delgado J, Voltz C, Stain M, Balkowiec-Iskra E, Mueller B, Wernsperger J, Malinowska I, Gisselbrecht C, Enzmann H, Pignatti F. The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia. Hemasphere. 2021 Jul 19;5(8):e616. doi: 10.1097/HS9.0000000000000616. eCollection 2021 Aug. PMID: 34291195; PMCID: PMC8288896.
Copy Download .nbib Format: NLM
Non-anesthesiologist sedation (NAS): The Italian retrotopia needs to be overcome.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Manno M, Biancheri P, Pignatti A, Becchi E, Gazzi M, Soriani P.
PMID: 34162510
Dig Liver Dis. 2021 Nov;53(11):1513-1514. doi: 10.1016/j.dld.2021.05.036. Epub 2021 Jun 20.

No abstract available.

Cite
Manno M, Biancheri P, Pignatti A, et al. Non-anesthesiologist sedation (NAS): The Italian retrotopia needs to be overcome. Dig Liver Dis. 2021;53(11):1513-1514doi: 10.1016/j.dld.2021.05.036.
Manno, M., Biancheri, P., Pignatti, A., Becchi, E., Gazzi, M., & Soriani, P. (2021). Non-anesthesiologist sedation (NAS): The Italian retrotopia needs to be overcome. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 53(11), 1513-1514. https://doi.org/10.1016/j.dld.2021.05.036
Manno, Mauro, et al. "Non-anesthesiologist sedation (NAS): The Italian retrotopia needs to be overcome." Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver vol. 53,11 (2021): 1513-1514. doi: https://doi.org/10.1016/j.dld.2021.05.036
Manno M, Biancheri P, Pignatti A, Becchi E, Gazzi M, Soriani P. Non-anesthesiologist sedation (NAS): The Italian retrotopia needs to be overcome. Dig Liver Dis. 2021 Nov;53(11):1513-1514. doi: 10.1016/j.dld.2021.05.036. Epub 2021 Jun 20. PMID: 34162510.
Copy Download .nbib Format: NLM
Mode of birth in women with low-lying placenta: protocol for a prospective multicentre 1:3 matched case-control study in Italy (the MODEL-PLACENTA study).

BMJ open

Ornaghi S, Colciago E, Vaglio Tessitore I, Abbamondi A, Antolini L, Locatelli A, Inversetti A, Pintucci A, Cetin I, Bracco B, Fabbri E, Sala V, Meroni M, Volpe G, Benedetti S, Bulfoni C, Marconi A, Lagrasta F, Paolini CL, Mazza E, Candiani M, Valsecchi L, Smid M, Pasi F, Pozzoni M, Castoldi M, Vignali M, Dal Molin G, Guarano A, Pellegrino A, Callegari C, Betti M, Lazzarin S, Prefumo F, Zanardini C, Parolin V, Catalano A, Barbolini E, Antonazzo P, Pignatti L, Tintoni M, Spelzini F, Martinelli A, Facchinetti F, Chiossi G, Vergani P.
PMID: 34873004
BMJ Open. 2021 Dec 06;11(12):e052510. doi: 10.1136/bmjopen-2021-052510.

INTRODUCTION: The term placenta praevia defines a placenta that lies over the internal os, whereas the term low-lying placenta identifies a placenta that is partially implanted in the lower uterine segment with the inferior placental edge located at 1-20...

Cite
Ornaghi S, Colciago E, Vaglio Tessitore I, et al. Mode of birth in women with low-lying placenta: protocol for a prospective multicentre 1:3 matched case-control study in Italy (the MODEL-PLACENTA study). BMJ Open. 2021;11(12):e052510doi: 10.1136/bmjopen-2021-052510.
Ornaghi, S., Colciago, E., Vaglio Tessitore, I., Abbamondi, A., Antolini, L., Locatelli, A., Inversetti, A., Pintucci, A., Cetin, I., Bracco, B., Fabbri, E., Sala, V., Meroni, M., Volpe, G., Benedetti, S., Bulfoni, C., Marconi, A., Lagrasta, F., Paolini, C. L., Mazza, E., Candiani, M., Valsecchi, L., Smid, M., Pasi, F., Pozzoni, M., Castoldi, M., Vignali, M., Dal Molin, G., Guarano, A., Pellegrino, A., Callegari, C., Betti, M., Lazzarin, S., Prefumo, F., Zanardini, C., Parolin, V., Catalano, A., Barbolini, E., Antonazzo, P., Pignatti, L., Tintoni, M., Spelzini, F., Martinelli, A., Facchinetti, F., Chiossi, G., & Vergani, P. (2021). Mode of birth in women with low-lying placenta: protocol for a prospective multicentre 1:3 matched case-control study in Italy (the MODEL-PLACENTA study). BMJ open, 11(12), e052510. https://doi.org/10.1136/bmjopen-2021-052510
Ornaghi, Sara, et al. "Mode of birth in women with low-lying placenta: protocol for a prospective multicentre 1:3 matched case-control study in Italy (the MODEL-PLACENTA study)." BMJ open vol. 11,12 (2021): e052510. doi: https://doi.org/10.1136/bmjopen-2021-052510
Ornaghi S, Colciago E, Vaglio Tessitore I, Abbamondi A, Antolini L, Locatelli A, Inversetti A, Pintucci A, Cetin I, Bracco B, Fabbri E, Sala V, Meroni M, Volpe G, Benedetti S, Bulfoni C, Marconi A, Lagrasta F, Paolini CL, Mazza E, Candiani M, Valsecchi L, Smid M, Pasi F, Pozzoni M, Castoldi M, Vignali M, Dal Molin G, Guarano A, Pellegrino A, Callegari C, Betti M, Lazzarin S, Prefumo F, Zanardini C, Parolin V, Catalano A, Barbolini E, Antonazzo P, Pignatti L, Tintoni M, Spelzini F, Martinelli A, Facchinetti F, Chiossi G, Vergani P. Mode of birth in women with low-lying placenta: protocol for a prospective multicentre 1:3 matched case-control study in Italy (the MODEL-PLACENTA study). BMJ Open. 2021 Dec 06;11(12):e052510. doi: 10.1136/bmjopen-2021-052510. PMID: 34873004.
Copy Download .nbib Format: NLM
A snapshot of exhaled nitric oxide and asthma characteristics: experience from high to low income countries.

Pulmonology

Pignatti P, Visca D, Loukides S, Märtson AG, Alffenaar JC, Migliori GB, Spanevello A.
PMID: 33358001
Pulmonology. 2022 Jan-Feb;28(1):44-58. doi: 10.1016/j.pulmoe.2020.10.016. Epub 2020 Dec 21.

Nitric oxide is a gas produced in the airways of asthmatic subjects and related to T2 inflammation. It can be measured as fractional nitric oxide (FeNO) in the exhaled air and used as a non-invasive, easy to evaluate, rapid...

Cite
Pignatti P, Visca D, Loukides S, et al. A snapshot of exhaled nitric oxide and asthma characteristics: experience from high to low income countries. Pulmonology. 2020;28(1):44-58doi: 10.1016/j.pulmoe.2020.10.016.
Pignatti, P., Visca, D., Loukides, S., Märtson, A. G., Alffenaar, J. C., Migliori, G. B., & Spanevello, A. (2022). A snapshot of exhaled nitric oxide and asthma characteristics: experience from high to low income countries. Pulmonology, 28(1), 44-58. https://doi.org/10.1016/j.pulmoe.2020.10.016
Pignatti, Patrizia, et al. "A snapshot of exhaled nitric oxide and asthma characteristics: experience from high to low income countries." Pulmonology vol. 28,1 (2022): 44-58. doi: https://doi.org/10.1016/j.pulmoe.2020.10.016
Pignatti P, Visca D, Loukides S, Märtson AG, Alffenaar JC, Migliori GB, Spanevello A. A snapshot of exhaled nitric oxide and asthma characteristics: experience from high to low income countries. Pulmonology. 2022 Jan-Feb;28(1):44-58. doi: 10.1016/j.pulmoe.2020.10.016. Epub 2020 Dec 21. PMID: 33358001.
Copy Download .nbib Format: NLM
Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders.

Frontiers in medicine

Mulder J, Verjans R, Verbaanderd C, Pean E, Weemers J, Leufkens HGM, Pignatti F, de Boer A, Voest EE, Stoyanova-Beninska VV, Pasmooij AMG.
PMID: 34957158
Front Med (Lausanne). 2021 Dec 09;8:790782. doi: 10.3389/fmed.2021.790782. eCollection 2021.

After marketing authorisation, the development of a medicinal product often continues with studies investigating new therapeutic indications. Positive results can potentially lead to changes to the terms of the marketing authorisation, such as an extension of therapeutic indication(s). These...

Cite
Mulder J, Verjans R, Verbaanderd C, et al. Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders. Front Med (Lausanne). 2021;8:790782doi: 10.3389/fmed.2021.790782.
Mulder, J., Verjans, R., Verbaanderd, C., Pean, E., Weemers, J., Leufkens, H. G. M., Pignatti, F., de Boer, A., Voest, E. E., Stoyanova-Beninska, V. V., & Pasmooij, A. M. G. (2021). Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders. Frontiers in medicine, 8790782. https://doi.org/10.3389/fmed.2021.790782
Mulder, Jorn, et al. "Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders." Frontiers in medicine vol. 8 (2021): 790782. doi: https://doi.org/10.3389/fmed.2021.790782
Mulder J, Verjans R, Verbaanderd C, Pean E, Weemers J, Leufkens HGM, Pignatti F, de Boer A, Voest EE, Stoyanova-Beninska VV, Pasmooij AMG. Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders. Front Med (Lausanne). 2021 Dec 09;8:790782. doi: 10.3389/fmed.2021.790782. eCollection 2021. PMID: 34957158; PMCID: PMC8695872.
Copy Download .nbib Format: NLM
Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders.

Frontiers in medicine

Mulder J, Verjans R, Verbaanderd C, Pean E, Weemers J, Leufkens HGM, Pignatti F, de Boer A, Voest EE, Stoyanova-Beninska VV, Pasmooij AMG.
PMID: 34957158
Front Med (Lausanne). 2021 Dec 09;8:790782. doi: 10.3389/fmed.2021.790782. eCollection 2021.

After marketing authorisation, the development of a medicinal product often continues with studies investigating new therapeutic indications. Positive results can potentially lead to changes to the terms of the marketing authorisation, such as an extension of therapeutic indication(s). These...

Cite
Mulder J, Verjans R, Verbaanderd C, et al. Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders. Front Med (Lausanne). 2021;8:790782doi: 10.3389/fmed.2021.790782.
Mulder, J., Verjans, R., Verbaanderd, C., Pean, E., Weemers, J., Leufkens, H. G. M., Pignatti, F., de Boer, A., Voest, E. E., Stoyanova-Beninska, V. V., & Pasmooij, A. M. G. (2021). Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders. Frontiers in medicine, 8790782. https://doi.org/10.3389/fmed.2021.790782
Mulder, Jorn, et al. "Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders." Frontiers in medicine vol. 8 (2021): 790782. doi: https://doi.org/10.3389/fmed.2021.790782
Mulder J, Verjans R, Verbaanderd C, Pean E, Weemers J, Leufkens HGM, Pignatti F, de Boer A, Voest EE, Stoyanova-Beninska VV, Pasmooij AMG. Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders. Front Med (Lausanne). 2021 Dec 09;8:790782. doi: 10.3389/fmed.2021.790782. eCollection 2021. PMID: 34957158; PMCID: PMC8695872.
Copy Download .nbib Format: NLM
Nutrients and Pathways that Regulate Health Span and Life Span.

Geriatrics (Basel, Switzerland)

Pignatti C, D'Adamo S, Stefanelli C, Flamigni F, Cetrullo S.
PMID: 33228041
Geriatrics (Basel). 2020 Nov 19;5(4). doi: 10.3390/geriatrics5040095.

Both life span and health span are influenced by genetic, environmental and lifestyle factors. With the genetic influence on human life span estimated to be about 20-25%, epigenetic changes play an important role in modulating individual health status and...

Cite
Pignatti C, D'Adamo S, Stefanelli C, et al. Nutrients and Pathways that Regulate Health Span and Life Span. Geriatrics (Basel). 2020;5(4)doi: 10.3390/geriatrics5040095.
Pignatti, C., D'Adamo, S., Stefanelli, C., Flamigni, F., & Cetrullo, S. (2020). Nutrients and Pathways that Regulate Health Span and Life Span. Geriatrics (Basel, Switzerland), 5(4), . https://doi.org/10.3390/geriatrics5040095
Pignatti, Carla, et al. "Nutrients and Pathways that Regulate Health Span and Life Span." Geriatrics (Basel, Switzerland) vol. 5,4 (2020). doi: https://doi.org/10.3390/geriatrics5040095
Pignatti C, D'Adamo S, Stefanelli C, Flamigni F, Cetrullo S. Nutrients and Pathways that Regulate Health Span and Life Span. Geriatrics (Basel). 2020 Nov 19;5(4). doi: 10.3390/geriatrics5040095. PMID: 33228041; PMCID: PMC7709628.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 83 entries